InvestorsHub Logo
Followers 4
Posts 207
Boards Moderated 0
Alias Born 03/06/2022

Re: FitzyP33 post# 389888

Tuesday, 12/06/2022 1:08:21 PM

Tuesday, December 06, 2022 1:08:21 PM

Post# of 459910
No, Fitzy, Missling's bogey is not the 1-2 month timeline with which the peer reviewed article was published. The real bogey would be the conclusions of the article: "Lecanemab...resulted in moderately less decline on measurements of cognition but was associated with adverse events." I am confident that the upcoming review of Blarcamesine will be more positive than that.
Volume:
Day Range:
Bid:
Ask:
Last Trade Time:
Total Trades:
  • 1D
  • 1M
  • 3M
  • 6M
  • 1Y
  • 5Y
Recent AVXL News